| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yuxi Zhao, Hua Yuan, Ning Li, Lingying W. A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective. International journal of biological macromolecules. 2025-02-08. PMID:39922351. |
in this review, we summarise the recent evidence and future prospects of adcs targeting folate receptor alpha (frα), mesothelin, cadherin-6, napi2b, human epidermal growth factor receptor 2 (her2), dipeptidase 3 (dpep3), b7-h4 (vtcn1), claudin-6 (cldn6) and trophoblast antigen protein 2 (trop2), in order to enhance our understanding of the clinical applications of adcs and offer new insights for clinical practice and further research. |
2025-02-08 |
2025-02-11 |
human |
| Xu Cheng, Ping Li, Rongqi Jiang, Enqing Meng, Hao W. ADC: a deadly killer of platinum resistant ovarian cancer. Journal of ovarian research. vol 17. issue 1. 2024-10-05. PMID:39367438. |
it encapsulates the advancements and clinical trials of novel adcs that target specific antigens such as folate receptor alpha (frα), muc16, napi2b, mesothelin, dipeptidase 3(dpep3), and human epidermal growth factor receptor 2 (her2), as well as tissue factor, highlighting their potential anti-tumor efficacy and used in combination with other therapies. |
2024-10-05 |
2024-10-07 |
human |
| Giovanni Fucà, Ilaria Sabatucci, Mariachiara Paderno, Domenica Loruss. The clinical landscape of antibody-drug conjugates in endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2024-07-29. PMID:39074933. |
we focused particularly on the most promising antibody-drug conjugate targets in endometrial cancer under clinical investigation, such as human epidermal growth factor receptor 2 (her2), folate receptor alpha (frα), trophoblast cell-surface antigen-2 (trop2), and b7-h4. |
2024-07-29 |
2024-08-02 |
human |
| Fabian Wohlfromm, Kamil Seyrek, Nikita Ivanisenko, Olga Troitskaya, Dagmar Kulms, Vladimir Richter, Olga Koval, Inna N Lavri. RL2 Enhances the Elimination of Breast Cancer Cells by Doxorubicin. Cells. vol 12. issue 24. 2023-12-22. PMID:38132099. |
in particular, we used bt549 and mda-mb-231 triple-negative breast cancer (tnbc) cells, t47d estrogen receptor alpha (erα) positive cells, and skbr3 human epidermal growth factor receptor 2 (her2) positive cells. |
2023-12-22 |
2023-12-24 |
human |
| Konstantinos Venetis, Francesco Pepe, Carlo Pescia, Giulia Cursano, Carmen Criscitiello, Chiara Frascarelli, Eltjona Mane, Gianluca Russo, Beatrice Taurelli Salimbeni, Giancarlo Troncone, Elena Guerini Rocco, Giuseppe Curigliano, Nicola Fusco, Umberto Malapell. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing. Cancer treatment reviews. vol 121. 2023-10-21. PMID:37864956. |
activating mutations of the estrogen receptor alpha gene (esr1) are common mechanisms of endocrine therapy (et) resistance in hormone receptor-positive (hr + )/human epidermal growth factor receptor 2 (her2)-negative metastatic breast cancer (mbc). |
2023-10-21 |
2023-11-08 |
Not clear |
| Roger Kai-Cheong Nga. Outcomes of Third-Line Trastuzumab Deruxtecan in a Patient with De Novo Stage 4 HER2-Positive Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report. Life (Basel, Switzerland). vol 13. issue 9. 2023-09-28. PMID:37763255. |
this case report describes the treatment of a patient diagnosed with de novo stage 4 human epidermal growth factor 2 (her2)-positive gastric adenocarcinoma with enteroblastic differentiation (gaed), a rare and aggressive form of gastric cancer characterized by a tubulopapillary growth pattern and enteroblastic cell lineage markers such as gpc3, sall4, and alpha fetoprotein. |
2023-09-28 |
2023-10-07 |
human |
| Rebecca Kringel, Katrin Lamszus, Malte Mohm. Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future. Cells. vol 12. issue 13. 2023-07-14. PMID:37443804. |
to date, car-t cells directed against several target antigens in gbm including interleukin-13 receptor alpha 2 (il-13rα2), epidermal growth factor receptor variant iii (egfrviii), human epidermal growth factor receptor 2 (her2), and ephrin type-a receptor 2 (epha2) have been tested in preclinical and clinical studies. |
2023-07-14 |
2023-08-14 |
human |
| Jenny Karlsson, Urs B Hagemann, Véronique Cruciani, Christoph A Schatz, Derek Grant, Christine Ellingsen, Alexander Kristian, Shirin Katoozi, Dessislava Mihaylova, Steinar R Uran, Mari Suominen, Roger M Bjerke, Olav B Ryan, Alan Cuthbertso. Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model. Cancers. vol 15. issue 13. 2023-07-14. PMID:37444529. |
human epidermal growth factor receptor 2 (her2) is overexpressed in 15-30% of breast cancers but has low expression in normal tissue, making it attractive for targeted alpha therapy (tat). |
2023-07-14 |
2023-08-14 |
mouse |
| Maya Nourieh, Roseline Vibert, Mathilde Saint-Ghislain, Joanna Cyrta, Anne Vincent-Salomo. Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction. Histopathology. vol 82. issue 1. 2022-12-09. PMID:36482269. |
human epidermal growth factor receptor 2 (her2) overexpression is widely determined based on immunohistochemistry, while next-generation sequencing (ngs) is currently employed to assess the presence of molecular alterations, including breast cancer gene 1 (brca1) and 2 or phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (pik3ca) mutations, which are targets of these new approved therapies. |
2022-12-09 |
2023-08-14 |
human |
| Precious A Akinnusi, Samuel O Olubode, Ayomide O Adebesin, Toluwani A Nana, Sidiqat A Shodehind. Discovery of Promising Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for Personalized Breast Cancer Treatment. Cancer informatics. vol 21. 2022-10-10. PMID:36213305. |
as a result, treatment of breast cancer has now become more personalized based on the specific features of the tumor such as overexpression of growth factor receptors (epidermal growth factor receptor (egfr), human epidermal growth factor receptor 2 (her2)), hormone receptors (human estrogen receptor alpha (er)) and kinases involved in pivotal signaling associated with growth (phosphatidylinositol 3-kinase (pi3k)). |
2022-10-10 |
2023-08-14 |
human |
| Ruoxi Hong, Binghe X. Breast cancer: an up-to-date review and future perspectives. Cancer communications (London, England). 2022-09-08. PMID:36074908. |
treatment strategies for breast cancer vary by molecular features, including activation of human epidermal growth factor receptor 2 (her2), hormonal receptors (estrogen receptor [er] and progesterone receptor [pr]), gene mutations (e.g., mutations of breast cancer 1/2 [brca1/2] and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [pik3ca]) and markers of the immune microenvironment (e.g., tumor-infiltrating lymphocyte [til] and programmed death-ligand 1 [pd-l1]). |
2022-09-08 |
2023-08-14 |
human |
| Angeles C Tecalco-Cruz, Jesús Zepeda-Cervantes, Josué O Ramírez-Jarquín, Alberto Rojas-Ocho. Proteolysis-targeting chimeras and their implications in breast cancer. Exploration of targeted anti-tumor therapy. vol 2. issue 6. 2022-09-01. PMID:36046115. |
nearly 70% and 20% of bc cases are estrogen receptor alpha positive (erα+) and human epidermal growth factor receptor 2-positive (her2+), respectively; therefore, er and her2 targeted therapies have been employed in bc treatment. |
2022-09-01 |
2023-08-14 |
human |
| Hani Saghir, Srinivas Veerla, Martin Malmberg, Lisa Rydén, Anna Ehinger, Lao H Saal, Johan Vallon-Christersson, Åke Borg, Cecilia Hegardt, Christer Larsson, Alaa Haidar, Ingrid Hedenfalk, Niklas Loman, Siker Kimbun. How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast Cancer. Cancers. vol 14. issue 16. 2022-08-26. PMID:36010992. |
biomarkers of interest included estrogen receptor (er; specifically, the alpha variant), progesterone receptor (pgr), ki67, her2, and tumor molecular subtype. |
2022-08-26 |
2023-08-14 |
Not clear |
| Elizabeth A Dao, Saira J George, Meghan M Heberton, Omar Pacha, Craig A Kovitz, Anisha B Patel, Rhea M Phillip. Periorbital edema associated with alpelisib. Cancer treatment and research communications. vol 32. 2022-07-14. PMID:35834907. |
alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (pi3k) inhibitor approved for use in the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor (her2)-negative metastatic breast cancer in combination with fulvestrant. |
2022-07-14 |
2023-08-14 |
human |
| Lama A Helmy, Mohammed Abdel-Halim, Raghda Hassan, Aya Sebak, Haithem A M Farghali, Samar Mansour, Salma N Tamma. The other side to the use of active targeting ligands; the case of folic acid in the targeting of breast cancer. Colloids and surfaces. B, Biointerfaces. vol 211. 2021-12-26. PMID:34954516. |
in this work, intravenous administration of free fa to healthy female mice resulted in breast tissue dysplasia, hyperplasia and in the increased expression of human epidermal growth factor receptor-2 (her2), folate receptor (fr), cancer antigen 15-3 (ca15.3), vascular endothelial growth factor (vegf), signal transducer and activator of transcription 3 (stat3) and the pro-inflammatory cytokines, tumor necrosis factor alpha (tnfα), interleukin-6 (il-6) and interleukin-1β. |
2021-12-26 |
2023-08-13 |
mouse |
| J M de Jong, J P Hoogendam, A J A T Braat, R P Zweemer, C G Gerestei. The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review. Gynecologic oncology. vol 162. issue 2. 2021-11-22. PMID:34053747. |
folate receptor alpha (frα) and human epidermal growth factor receptor 2 (her2) are overexpressed in eoc in 80% and 20% of the cases, respectively, and have been previously studied as a target for intraoperative imaging. |
2021-11-22 |
2023-08-13 |
human |
| Zhang Wei, Fei Sijia, Tong Rui, Liu Yang, He Jianjun, Wan Bin, Xu Jin. Analysis of differentially expressed proteins between HER2 positive and triple negative breast cancer and their prognostic significance. Annals of diagnostic pathology. vol 55. 2021-11-17. PMID:34610510. |
both triple negative breast cancer (tnba) and her2-positive breast cancer lack expression of estrogen receptor alpha (er) and progesterone receptor (pr), while human epidermal growth factor receptor 2 (her2) in tnbc is also negative. |
2021-11-17 |
2023-08-13 |
human |
| María Teresa Cervantes-Díaz, Patricia Piña-Sánchez, Yelda Aurora Leal-Herrer. The use of biomarkers in breast cancer. Revista medica del Instituto Mexicano del Seguro Social. vol 58. issue Supl 1. 2021-10-27. PMID:34695319. |
in this review are presented some biomarkers that are routinely used in clinical oncology practice and have a well-established clinical value to direct treatment and establish prognosis in patients with breast cancer, such as er-alpha (estrogen receptor alpha), pr (progesterone receptor), her2 (human epidermal growth factor receptor 2), ki-67 (marker of proliferation ki-67), and other biomarkers, such as multigenic signatures, which are used more and more frequently, due to the clinical value shown in various randomized clinical trials and for being increasingly accessible in daily clinical practice. |
2021-10-27 |
2023-08-13 |
human |
| Jie Gao, Fang Li, Zihao Liu, Mengli Huang, Huoming Chen, Guoqing Liao, Jichang Meng, Qing Wang, Hui Zhao, Chenxi Li, Jing Ji, Shangli Cai, Nan D. Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study. Medicine. vol 100. issue 35. 2021-09-10. PMID:34477158. |
the vascular endothelial growth factor-related signature analysis indicated vascular endothelial factor a expression was upregulated with egfr alterations (p = .034) which may be involved in bv resistance, and her2 alterations were associated with hypoxia inducible factor 1 subunit alpha overexpression significantly (p = .029).egfr or her2 alterations are negative predictors of pfs for oc patient treated with bv plus chemotherapy. |
2021-09-10 |
2023-08-13 |
human |
| Sara Elena Rebuzzi, Lodovica Zullo, Giovanni Rossi, Massimiliano Grassi, Veronica Murianni, Marco Tagliamento, Arsela Prelaj, Simona Coco, Luca Longo, Maria Giovanna Dal Bello, Angela Alama, Chiara Dellepiane, Elisa Bennicelli, Umberto Malapelle, Carlo Genov. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. International journal of molecular sciences. vol 22. issue 5. 2021-04-22. PMID:33807876. |
this review aims to cover the molecular alterations with a potential clinical impact in nsclc, including amplifications or mutations of the mesenchymal-epithelial transition factor (met), fusions of rearranged during transfection (ret), rearrangements of the neurotrophic tyrosine kinase (ntrk) genes, mutations of the kirsten rat sarcoma viral oncogene (kras) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (pik3ca), as well as amplifications or mutations of human epidermal growth factor receptor 2 (her2). |
2021-04-22 |
2023-08-13 |
human |